IC
KZR

Ikarian Capital’s Kezar Life Sciences KZR Stock Holding History

Ikarian Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$758K Hold
102,211
– – 0.06% 115
2025
Q4 		$643K Sell
102,211
-4,690
-4% -$27.4K 0.05% 134
2025
Q3 		$417K Hold
106,901
– – 0.04% 142
2025
Q2 		$490K Hold
106,901
– – 0.09% 91
2025
Q1 		$522K Hold
106,901
– – 0.06% 115
2024
Q4 		$718K Buy
106,901
+2
+0% +$15 0.1% 120
2024
Q3 		$827K Buy
106,899
+20,000
+23% +$121K 0.12% 104
2024
Q2 		$521K Hold
86,899
– – 0.09% 94
2024
Q1 		$783K Buy
86,899
+1,560
+2% +$14.2K 0.09% 110
2023
Q4 		$809K Hold
85,339
– – 0.08% 105
2023
Q3 		$1.02M Buy
85,339
+1,179
+1% +$20.9K 0.12% 99
2023
Q2 		$2.06M Hold
84,160
– – 0.33% 64
2023
Q1 		$2.63M Buy
84,160
+21,161
+34% +$1.22M 0.6% 51
2022
Q4 		$4.44M Sell
62,999
-9,860
-14% -$731K 1.07% 31
2022
Q3 		$6.27M Sell
72,859
-67,953
-48% -$6.6M 1.25% 28
2022
Q2 		$11.6M Buy
140,812
+32,500
+30% +$2.87M 2.12% 14
2022
Q1 		$18M Buy
108,312
+6,220
+6% +$893K 2.37% 12
2021
Q4 		$17.1M Buy
+102,092
New +$11.5M 2.54% 8

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Ikarian Capital's KZR Position: Q1 2026 in Review

Ikarian Capital held its Kezar Life Sciences (KZR) position steady in Q1 2026 at 102,211 shares worth $758K. The position accounts for 0.06% of the portfolio, ranked #115.

Ikarian Capital first reported a position in KZR in Q4 2021 and has held it in 18 quarters since. The position peaked at $18M in Q1 2022. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Ikarian Capital held 102,211 shares of Kezar Life Sciences worth $758K as of Q1 2026.
  • Ikarian Capital left its Kezar Life Sciences share count unchanged in Q1 2026.
  • Kezar Life Sciences made up 0.06% of Ikarian Capital's portfolio in Q1 2026, its #115 holding.
  • Ikarian Capital first reported a position in Kezar Life Sciences in Q4 2021 and has held it in 18 quarters since.
  • Ikarian Capital's Kezar Life Sciences position peaked at $18M in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.